Remember meForgot password?
    Log in with Twitter
Press Release

Global Type 1 Diabetes Market 2016-2020 - New Report Available

Fast Market Research announces the availability of the new TechNavio report, "Global Type 1 Diabetes Market 2016-2020", on their comprehensive research portal

This press release was orginally distributed by SBWire

Boston, MA -- (SBWIRE) -- 04/14/2016 -- Diabetes, often referred to as diabetes mellitus, results in high blood glucose levels. Depending on the cause of development, it can be divided into three types:

-Type 1 diabetes (or insulin-dependent diabetes mellitus): The pancreas do not produce the required amount of insulin in the body, leading to high blood glucose levels.
-Type 2 diabetes (non-insulin-dependent diabetes mellitus): In this condition, though the body produces the required amount of insulin, the cells do not respond to it. This results in a high glucose level in the body.
-Gestational diabetes: This condition occurs in pregnant women without any history of diabetes.

Type 1 diabetes is an autoimmune disorder characterized by high blood glucose levels. In this condition, the immune system is activated against insulin-producing cells. This condition hampers the body's ability to produce insulin and disrupts blood glucose homeostasis. Type 1 diabetes differs from a more prevalent form of diabetes mellitus, type 2 diabetes, wherein the insulin is produced inside the body. Type 1 diabetes accounts for only 5%-15% of the total diabetes cases. As the disease is more prevalent among children and adolescents aged 0-15 years, it was earlier known as juvenile diabetes. Type 1 diabetes management relies on providing symptomatic relief and improving the quality of life of people.

Get More Details on this Report and a Full Table of Contents at Global Type 1 Diabetes Market 2016-2020

Technavio's analysts forecast the global type 1 diabetes drugs market to grow at a CAGR of 8.05% during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global type 1 diabetes drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded drugs and biosimilars used to treat and prevent type 1 diabetes.

The market is divided into the following segments based on geography:


Technavio's report, Global Type 1 Diabetes Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

-Eli Lilly and Company
-Novo Nordisk A/S
-Sanofi SA

Other prominent vendors

-Astellas Pharma
-BHV Pharma
-Boehringer Ingelheim
-Dance Biopharm
-Diamyd Therapeutics AB
-Diasome Pharmaceuticals
-Gan & Lee Pharmaceuticals
-Generex Biotechnology
-ILTOO Pharma
-Islet Sciences
-Kotobuki Pharmaceutical
-Lexicon Pharmaceuticals
-Living Cell Technologie
-MannKind Pharmaceuticals
-Merrion Pharmaceutical
-Oramed Pharmaceuticals
-Osiris Therapeutics
-Perle Biosciences
-Strongbridge Biopharma
-Xeris Pharmaceuticals

Market driver

-Increase in prevalence of type 1 diabetes
-For a full, detailed list, view our report

Market challenge

-Poor storage conditions and distribution policies for insulin
-For a full, detailed list, view our report

Market trend

-Awareness programs and initiatives
-For a full, detailed list, view our report

Key questions answered in this report

-What will the market size be in 2020 and what will the growth rate be?
-What are the key market trends?
-What is driving this market?
-What are the challenges to market growth?
-Who are the key vendors in this market space?
-What are the market opportunities and threats faced by the key vendors?
-What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Companies Mentioned in this Report: Eli Lilly and Company, Novo Nordisk A/S, Sanofi SA, Adocia, Astellas Pharma, AstraZeneca, Baxalta, BHV Pharma, Biocon, Biodel, Boehringer Ingelheim, CureDM, Dance Biopharm, Diamyd Therapeutics AB, Diasome Pharmaceuticals, DiaVac, Exsulin, Gan & Lee Pharmaceuticals, Generex Biotechnology, GlaxoSmithKline, ILTOO Pharma, Intrexon, Islet Sciences, Kamada, Kotobuki Pharmaceutical, Lexicon Pharmaceuticals, Living Cell Technologie, MacroGenics, MannKind Pharmaceuticals, Merck, Merrion Pharmaceutical, Oramed Pharmaceuticals, Osiris Therapeutics, Perle Biosciences, Pfizer, REGiMMUNE, Strongbridge Biopharma, Toleranzia, Tolerio, Xeris Pharmaceuticals, XOMA

About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

-Global Type 2 Diabetes Market 2016-2020
-Active Pharmaceutical Ingredient Market - Global Forecast to 2020
-Type 1 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Innovative and Diversified Pipeline to Drive Market Growth Despite Patent Expirations
-Type 2 Diabetes Mellitus Therapeutics in Asia-Pacific Markets to 2021 - Increasing Usage of Newer Therapies and Expanding Treatment Population to Encourage Robust Growth
-Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to 2021 - Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth

For more information on this press release visit:

Media Relations Contact

Bill Thompson
Director of Marketing
Fast Market Research, Inc.
Telephone: 800-844-8156
Email: Click to Email Bill Thompson

Latest News
Top News